NEWS AND LAUNCHES
Since December 2019, a new type of pneumonia defined as coronavirus disease 2019 (COVID-19) is spreading worldwide and affecting an increasing number of people every day. Main symptoms are fever and cough, and most of patients recover spontaneously.
However, about 1 in 6 patients can develop breathing difficulties and in some of them the disease progresses to a more systemic disease and multiple organ dysfunction (1). Patient’s risk stratification is key to optimize COVID-19 patients flow at hospital. Stratification is currently based on characteristics of severe pneumonia and on laboratory findings.
21 TARGETS IN ONE TEST
The BioFire RP2 Panel uses a syndromic approach to accurately detect and identify the pathogens most commonly associated with respiratory infections. Fast and comprehensive, the BioFire RP2 Panel offers an unprecedented run time of about 45 minutes, enabling higher efficiency and throughput on the BioFire® FilmArray® 2.0 and the BioFire® FilmArray® Torch Systems. Rapid respiratory PCR test results may enable better-informed diagnosis and treatment of patients. Quick turnaround on a broad menu of pathogens may also help clinicians make vital decisions regarding admission, isolation, cohorting, and additional diagnostic testing.
BioMérieux, a world leader in the field of in vitro diagnostics, today announced performance validation and the upcoming launch of VIDAS® anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to the SARS-CoV-2 that causes the COVID-19 disease.
Building on years of experience in developing immunoassays, bioMérieux worked closely with several hospitals to develop and validate the performances of two tests. VIDAS® anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG will identify in less than 30 minutes the presence of antibodies in people who have been infected with SARS-CoV-2. In this context, clinical specificity is particularly important to ensure that testing of uninfected individuals consistently shows a negative result. Both VIDAS® anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG demonstrated excellent clinical specificity data.
FAS in ACTION
FilmArray at the RITM
FAS Diagnostic Group, Inc. as part of its commitment to only provide the best solutions against the coronavirus pandemic, had a FilmArray Respiratory Panel 2.1 evaluated at the Research Institute for Tropical Medicine.
We are now officially RITM evaluated!
We are proud to announce that FilmArray RP 2.1 was graded 100% specific and 100% sensitive by the RITM.
What is more special is that findings show that co-infections were quickly tested and identified using the system on COVID-19 positive samples. On the other hand, COVID-19 negative samples tested positive on other pathogens.
THIS IS TRULY THE GAME CHANGER!
All these result, in 45 minutes!
FAS for Frontliners
As we continue to face this battle against COVID-19, FAs diagnostic group will continue to serve and support you, our dear Frontliners. We thank you for the opportunity to be your partner in healthcare.
We appreciate you sending messages and photos to thank us, and with all our hearts, you are all welcome. But, it is you we have to thank.
No words could express how much we appreciate you, our laboratory partners nationwide. We hope that the small token of gratitude you receive from us these past three week, at least, made you smile (and made your tummies full). People may not know what you do inside the laboratory, but we see you, we know, and we salute you.
Together, we will win.